Global Flu Treatment Market – Industry Trends and Forecast to 2030

Flu Treatment Market Analysis and Size

The primary factor which contributes to the growth of the flu treatment market includes a surge in incidences of influenza worldwide. According to the World Health Organization (WHO), the disease accounts for upto 5 million severe cases and 650,000 deaths every year. The wide availability of the treatment and new drugs under process can also increase the growth of this market.  It has been witnessed that many of the flu drugs have shown promise in the treatment of coronavirus.

 Data Bridge Market Research analyses a growth rate in the flu treatment market in the forecast period 2023-2030. The expected CAGR of flu treatment market is tend to be around 5% in the mentioned forecast period. The market is valued at USD 1047.16 million in 2022, and it would grow upto USD 1547.13 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Flu Treatment Market Scope and Segmentation

​​​​​​​

Market Definition

Flu which is also called influenza is a common type of viral infection. The common symptoms of flu are chills, muscle aches, fever, headaches, runny nose, cough and others. In case of flu, the respiratory tract is manly affected. There are four major types of influenza viruses: influenza A, influenza B, influenza C, and influenza D. The most common types of influenza virus responsible for seasonal flu each year are type A and B.   

Flu Treatment Market Dynamics

Drivers

• Increasing Clinical Research Activities

There are several factors such as a surge in healthcare expenditure, and an increase in R&D investments associated with anti-viral drugs further boost the influenza treatment market growth. For instance, F. Hoffmann-La Roche AG launched Xofluza (Baloxavir Marboxil) for the treatment of influenza in 2018. Additionally, Xofluza is the first new flu medicine with a novel proposed mechanism of action. Thus, this leads to the wide availability of better treatment options for patients. Conversely, the high growth potential shown by developing economies such as India and China having a huge population base and famous epidemiology of influenza infection is anticipated to provide lucrative opportunities for the market during the forecast period 2023-2030. Additionally, Pfizer announced to initiation phase 3 clinical trial of the influenza vaccine in September 2022. The company employed mRNA technology to gain insights into more effective vaccines that can minimize rates of flu-related hospitalization and death. Thus, this boosts the market growth.

Opportunities

• Increasing Government Initiatives

The increasing government initiatives to combat flu and develop accurate tests will complement the market growth. For instance, Qorvo Biotechnologies was awarded a USD 4.1 million worth contract from the National Institute of Health in February 2022 to accelerate the process of developing the COVID-19/Flu Combo assay and its antigen test. The funds will be used in several clinical trials and market launches of the products. Thus, this factor boost the market growth.

• Rising Prevalence of Influenza Cases in Elderly Population

The increasing base of the elderly population increases the probability of a higher occurrence rate of flu. Thus, one of the WHO’s recommendations to prevent influenza cases is to vaccinate elder individuals aged above the age of 65 years. In 2018-19, about 55% of hospitalization because of the flu was accounted for by the elderly population, i.e., 65+ years adults. Likewise, 75% of flu-related deaths are among older adults. Therefore, the low immune system of older adults makes them more susceptible to the flu virus. Thus, this boost the market growth

Restraints/Challenges

• High Cost of Treatment

The increasing cost of developing tests and devices can impede the growth of the market. The raw material availability and accessibility constraints inflate the overall cost of the product. The increasing burden of high production costs is passed on to the end-users at high prices. For instance, the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test is an at-home collection kit for multiple respiratory viruses including flu. The test kit cost is about USD 169 at retail and online stores. This impedes the market growth.

This flu treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the flu treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Flu Treatment Market Scope

The flu treatment market is segmented on the basis of types, medication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Type A
• Type B
• Type C

Medication

• Antiviral drugs
• Antihistamines
• Analgesics
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Flu Treatment Market Regional Analysis/Insights

The flu treatment market is analyzed and market size insights and trends are provided by types, medication, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the flu treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for flu treatment market throughout the forecasted period because of the focus of global players on novel technology. Also, the U.S. healthcare authority launched COVID-19 and flu virus testing guidance for Clinicians. Sveral manufacturers of these players include Becton Dickinson & Co., Quidel Corp., and Roche Molecular Systems, Inc.

Asia-Pacific dominates the market because of the increasing incidence of influenza cases. Europe is also considered to hold bright growth prospects in the upcoming years. Numerous South-East Asia and pacific regions have collaborated with international organizations, such as WHO, to address many of the challenges such as lack of flu-positive samples, low representatives to collect the specimens, and difficulty to ship the samples.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Flu Treatment Market Share Analysis

The flu treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to flu treatment market

Key players operating in the flu treatment market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• AstraZeneca (U.K.)
• GSK plc (U.K.)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• NATCO Pharma Limited (India)
• Mylan N.V. (U.S.)
• Sanofi (France)
• Bayer AG (Germany)

SKU-52895